



DCAT
TOP
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. Stada Receives New Acquisition Offer

Nidda Healthcare, the acquiring company of Bain Capital and Cinven Partners, will submit a renewed binding voluntary public takeover offer for all outstanding shares of Stada Arzneimittel AG, a Bad Vibel, Germany-based generic and over-the-counter drug company, which is EUR 16 million (\$18.3 million) above the original offer of EUR 5.318 billion (\$5.63 billion) made in April. [Read More](#)

2. Merck KGaA To Invest \$100 Million in Site Network and Cut Jobs in Life-Sciences Business

Merck KGaA has announced its current site network for its life-sciences business in Western Europe will be refined as the company's life-sciences business invests EUR 90 million (\$102.7 million) in four sites in Germany, Switzerland and France. The company also plans to relocate activities at certain sites in Germany, resulting in a reduction of 200 positions. [Read More](#)

3. Eli Lilly Wins UK Patent Case for Cancer Drug Alimta

Eli Lilly and Company has received a favorable ruling from the UK Supreme Court regarding patent litigation for Alimta (pemetrexed disodium), which is used to treat certain forms of lung cancer. Alimta is one of Lilly's top-selling drugs with global 2016 sales of \$2.3 billion. [Read More](#)

4. Sanofi to Acquire Protein Sciences in Deal Worth Up To \$750 Million

Sanofi has agreed to acquire Protein Sciences, a vaccines developer and manufacturer, for an upfront payment of \$650 million and up to \$100 million upon achievement of certain milestones. [Read More](#)

5. Shire Gains Preliminary Injunction Against Roche

Shire has obtained a preliminary injunction in a court in Hamburg, Germany against Roche to address what it says are "incomplete and misleading statements" regarding its investigational treatment, emicizumab, a drug to treat hemophilia. [Read More](#)

6. Endo Voluntarily Withdraws Opioid Drug

Endo International has decided to voluntarily remove Opana ER (oxycodone hydrochloride extended release), an opioid agonist for severe pain management. Its decision follows a request by the FDA to voluntarily withdraw the drug due to its high potential for abuse, marking the first time the FDA has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. [Read More](#)

7. FDA Advisory Committee Recommends Novartis' CAR T Therapy and Pfizer's Antibody Drug Conjugate for Approval

An FDA Advisory Committee has recommended for approval Novartis' chimeric antigen receptor T cell (CAR-T) therapy, tisagenlecleucel, for treating relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia, providing the potential for the first CAR T approval in the US. Also, the committee recommended for approval, Pfizer's antibody drug conjugate, Mylotarg (gemtuzumab ozogamicin), for treating acute myeloid leukemia. The news is part of DCAT Value Chain Insights Pipeline News [Read More](#)

8. [Biocon Cited for Manufacturing Issues](#)

Biocon, a Bangalore, India-based pharmaceutical manufacturer, has been cited by French regulatory authorities for GMP deficiencies in a drug-product manufacturing plant making several proposed biosimilars, including pegfilgrastim (reference product, Amgen's Neulasta) and trastuzumab (reference product, Roche's Herceptin). Biocon is partnered with Mylan for these and other biosimilars. [Read More](#)

9. [Eurofins to Acquire Amatsigroup for Nearly \\$150 Million](#)

Eurofins Scientific, a biopharmaceutical analytical testing firm, has agreed to acquire the Amatsigroup, a CDMO providing preclinical and clinical phase services, for approximately EUR 130 million (\$149 million) plus some residual debt at closing. [Read More](#)

10. [Eli Lilly, Purdue University in Pact for Injectable Drug Delivery](#)

Eli Lilly and Company and Purdue University have formed a five-year, \$52-million strategic collaboration for improving delivery of injectable medicines to reduce pain, decrease the number of injections, and enable better patient compliance and overall health. [Read More](#)

The DCAT organization is happy to provide this service to its members each Friday. Have a great weekend!

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcat.org